[PDF] Top 20 A methodological framework for drug development in rare diseases
Has 10000 "A methodological framework for drug development in rare diseases" found on our website. Below are the top 20 most common "A methodological framework for drug development in rare diseases".
A methodological framework for drug development in rare diseases
... Randomization does not ensure equality for all prognos- tic factors in the treatment groups, especially with small sample sizes, but it does ensure that confidence intervals and p-values are validated using probability ... See full document
10
Applicability and added value of novel methods to improve drug development in rare diseases
... Within the ASTERIX project 13 novel methods have been developed proposing innovative approaches to adapt and analyse clinical trials on small populations and rare diseases (Table 1). We aimed to evaluate ... See full document
16
ORPHAN DRUGS: NEED OF AN HOUR
... Rare diseases and orphan drugs have been boons to applied pharmaceutical ...of Drug Development found that from 1983 to 1992 the biotech industry secured 19 percent of all orphan drug ... See full document
14
Rare disease registries: potential applications towards impact on development of new drug treatments
... to rare diseases, ran- domized studies can still be conducted, as in many diseases the patient population is large enough to per- form successful random ...possibilities, rare diseases ... See full document
11
Drug development for exceptionally rare metabolic diseases: challenging but not impossible
... the drug described in a publication of preclinical proof of concept or in a case report was similar to the drug included in the orphan designation ...both rare diseases with and without an ... See full document
9
Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act
... single rare diseases is complicated by the small size of available study populations and the slowly progressive nature of most diseases ...successful drug development ... See full document
9
Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints
... common diseases with similar ...the rare disease and common diseases, these tests should be considered to have predictive ...common diseases where the clin- ical physiologic measure is ... See full document
17
Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada
... deliberative framework may have contrib- uted to the increase in positive ...a framework for CDR in which price reduction was added as a condition for listing the ...The framework also included a ... See full document
11
Sustainable rare diseases business and drug access: no time for misconceptions
... the development of new me- dicines for complex ...and development of tomorrow’s ...any drug, including OMP, is the unique R&D and financial invest- ment process required to bring a product to ... See full document
9
European Reference networks for rare diseases: what is the conceptual framework?
... Networks in highly specialised health care are hybrid structures composed of several types of networks with different levels of collaboration. There is normally a core of players, who work together based on contracts ... See full document
9
Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
... very rare (orphan) diseases, the clinical trials included a very limited number of patients treated under very controlled ...original drug approval dossier included data on a total of 78 CAPS ... See full document
8
Rare diseases under different levels of economic analysis: current activities, challenges and perspectives
... the development and reimbursement of ODs (ie, drugs that are able to treat diseases so rare that, under usual market conditions, pharmaceutical companies are reluctant to develop them) and in the ... See full document
8
Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases
... The development of new drugs is a long and complex process, with extremely high investment and small expectation of ...and development (R&D) process. Drug Discovery programs are pursuing ... See full document
9
Investigating the landscape of US orphan product approvals
... phan drug approvals between 1983—2017, including both orphan NME drugs and secondary orphan ...orphan drug approvals occurred during this ...the development of drugs for rare diseases ... See full document
8
Drug discovery and development for neglected diseases: the DND<em>i</em> model
... NTD drug development relies on strong partnerships between industry and academia, and on sharing of knowledge that is often held as proprietary by different ...TPPs, drug discovery manuals, critical ... See full document
7
Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study
... of rare diseases are not well ...Overall, rare disease diagnosis presents itself as a cognitive chal- lenge due to a combination of factors that characterize rare diseases and ... See full document
12
The past is the present: a cross-cultural exploration of the literary displacement of Indigenous people using a relational discourse
... This methodological framework was designed to overcome a subliminal racist consciousness inherited (in my instance) from literature, learning and previous ... See full document
154
GENETIC IMPLICATIONS OF RARE DISEASES
... Pediatrics is owned, published, and trademarked by the Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has.[r] ... See full document
5
Epigenetic understanding of gene-environment interactions in psychiatric disorders: a new concept of clinical genetics
... Recent sequencing technology has led to a precise understanding of the sequence structure of the human genome, and revealed the presence of copy-number var- iations (CNVs), which are associated with susceptibility to ... See full document
8
Translational and Regulatory Challenges for Exon Skipping Therapies
... therapeutic development of antisense- mediated exon skipping approaches for rare ...for rare diseases, such as small patient numbers and limited information on natural history and ... See full document
25
Related subjects